UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2022 001-36345 (Commission File Number) GALMED PHARMACEUTICALS LTD. (Exact name of Registrant as specified in its charter) 16 Tiomkin St. Tel Aviv 6578317, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Fo ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Naz Rahman - Maxim Group Operator Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year-end 2021. Today’s conference is being recorded. Before we begin, please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of eve ...

Exhibit 99.1 Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, May. 2, 2022 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibro ...

| --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------| | | | | | | Clinical antifibrotic effect of Aramchol™: | | | | Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne Université, ARMOR study coprincipal investigator November 2021 1 Safe Harbor and Disclaimer Statement This presentation contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, r ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q3 2021 Earnings Conference Call November 8, 2021 8:30 AM ET Company Participants Allen Baharaff - President and Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scientific Officer Vlad Ratziu - Professor, Hepatology, Sorbonne Université Conference Call Participants Ryan Deschner - Raymond James Thomas Yip - H.C. Wainwright Justin Zelin - BTIG Operator Good day and welcome to the Galmed Conference Call to discuss Financial Resu ...

| --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------| | | | | | | Clinical antifibrotic effect of Aramchol™: | | | | Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne Université, ARMOR study coprincipal investigator November 2021 1 Safe Harbor and Disclaimer Statement This presentation contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, r ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q2 2021 Results Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Allen Baharaff - President, Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scientific Officer Conference Call Participants Edward Nash - Canaccord Genuity Kristen Kluska - Cantor Fitzgerald Timur Ivannikov - Raymond James Operator Good day and welcome to Galmed conference call to discuss financial results for the second quarter 2021. Today ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Liat Hayardeny - Chief Scientific Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Thomas - H.C. Wainwright Rick - Cantor Fitzgerald Operator Good day. Welcome to the Galmed Conference Call to discuss Financial Results for the First Quarter 2021. Today's conference is being rec ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Steve Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good day. Welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year Ended 2020. Today's conference is being recorded. Before ...